Rbf Capital, LLC Affimed N.V. Transaction History

Rbf Capital, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2019 May 15, 2019	SELL	$3.05 - $4.34 $49,098 - $69,865	-16,098 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$1.45 - $6.15 $15,609 - $66,204	-10,765 Reduced 40.07%	16,098 $70,000
Q2 2018 Aug 14, 2018	SELL	$1.65 - $2.5 $9,406 - $14,252	-5,701 Reduced 17.51%	26,863 $46,000
Q4 2017 Feb 14, 2018	BUY	$1.23 - $2.3 $40,053 - $74,897	32,564	32,564 $42,000

1.09M

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

Get notified when there are updates to the investment portfolio of Rbf Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Rbf Capital, LLC with notifications on news.